The test is called Videssa Breast and is made by Provista Diagnostics. A team led by Dr. Ana Lourenco of Warren Alpert Medical School at Brown University conducted two prospective trials that included 545 women with mammograms categorized as BI-RADS 3 or 4 (probably benign and suspicious for abnormality).
The researchers found that Videssa Breast had a cancer sensitivity of 87.5%, a specificity of 83.8%, a positive predictive value of 25.2%, and a negative predictive value of 99.1%.
The test is currently in limited clinical use through an early-access program, Provista Diagnostics said.
Copyright © 2017 AuntMinnie.com